BioNTech sees $3.3B revenue for 2024, expanding into oncology

BioNTech, the company known for developing the COVID-19 vaccine with Pfizer, expects revenues in 2024 to be around €3 billion, it said in a statement on Tuesday. The forecast is part of the compa…